✦ LIBER ✦

Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer

✍ Scribed by Yan-Xia Shi; Yu-Ting Tan; Zhong-Yu Yuan; Shu-Sen Wang; Rou-Jun Peng; Xin An; Ye Cao; Ying Jin; Xiu-Yu Cai; Yue-Li Sun; Xiao-Yu Teng; Dong-Geng Liu

Book ID: 107577411
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 345 KB
Volume: 29
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-010-9798-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trastuzumab Emtansine: A Review of Its U

Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy

✍ Dhillon, Sohita 📂 Article 📅 2014 🏛 Springer International Publishing AG 🌐 English ⚖ 402 KB

Survival, healthcare resource use and co

Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

✍ Kathleen Lang,Huan Huang,Medha Sasane… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 636 KB

CNS relapses in patients with HER2-posit

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

✍ Pestalozzi, Bernhard C; Holmes, Eileen; de Azambuja, Evandro; Metzger-Filho, Ott 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 198 KB

Clinical outcomes in patients who receiv

Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology

✍ Kaplan, Muhammet Ali; Isikdogan, Abdurrahman; Koca, Doğan; Kucukoner, Mehmet; Gu 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 245 KB

PO57 COMPARISON OF DOCETAXEL PLUS TRASTU

PO57 COMPARISON OF DOCETAXEL PLUS TRASTUZUMAB (DT) AND VINORELBINE PLUS TRASTUZUMAB (VT) AS FIRST-LINE THERAPY OF ANTHRACYCLINE PRE-TREATED METASTATIC OR LOCALLY ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER (A SUB-GROUP ANALYSIS OF THE HERNATA STUDY)

✍ Langkjer, Sven T.; Bjerre, Karsten; Lidbrink, Elisabet; Wist, Erik; Andersson, M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB